JP2021532114A5 - - Google Patents

Info

Publication number
JP2021532114A5
JP2021532114A5 JP2021503581A JP2021503581A JP2021532114A5 JP 2021532114 A5 JP2021532114 A5 JP 2021532114A5 JP 2021503581 A JP2021503581 A JP 2021503581A JP 2021503581 A JP2021503581 A JP 2021503581A JP 2021532114 A5 JP2021532114 A5 JP 2021532114A5
Authority
JP
Japan
Prior art keywords
cells
age
antibody
modified
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021503581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532114A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/043071 external-priority patent/WO2020023532A1/en
Publication of JP2021532114A publication Critical patent/JP2021532114A/ja
Publication of JP2021532114A5 publication Critical patent/JP2021532114A5/ja
Pending legal-status Critical Current

Links

JP2021503581A 2018-07-23 2019-07-23 放射線曝露及び化学物質曝露の慢性影響を治療するための方法及び組成物 Pending JP2021532114A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862702229P 2018-07-23 2018-07-23
US62/702,229 2018-07-23
PCT/US2019/043071 WO2020023532A1 (en) 2018-07-23 2019-07-23 Methods and compositions for treating chronic effects of radiation and chemical exposure

Publications (2)

Publication Number Publication Date
JP2021532114A JP2021532114A (ja) 2021-11-25
JP2021532114A5 true JP2021532114A5 (https=) 2023-05-26

Family

ID=67777383

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021503581A Pending JP2021532114A (ja) 2018-07-23 2019-07-23 放射線曝露及び化学物質曝露の慢性影響を治療するための方法及び組成物

Country Status (4)

Country Link
US (1) US20220175916A1 (https=)
EP (1) EP3826670A1 (https=)
JP (1) JP2021532114A (https=)
WO (1) WO2020023532A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
EP3194439B1 (en) 2014-09-19 2022-01-19 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
US20230181730A1 (en) * 2020-05-01 2023-06-15 Siwa Corporation Methods of treating infections
WO2022093195A1 (en) * 2020-10-27 2022-05-05 Siwa Corporation Methods and compositions for treating osteoarthritis using anti-age antibodies or age antigens
WO2022125776A2 (en) * 2020-12-09 2022-06-16 Siwa Corporation Methods and compositions for treating kidney diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5624804A (en) 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
EP1988918A4 (en) 2006-02-22 2010-04-28 Novavax Inc ADJUVANZ AND VACCINE COMPOSITIONS
RU2553225C2 (ru) * 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
ES2725852T3 (es) * 2010-09-27 2019-09-27 Siwa Corp Eliminación selectiva de células modificadas por AGE para el tratamiento de la aterosclerosis
MX2014007093A (es) * 2011-12-13 2014-10-13 Buck Inst For Res On Aging Metodos para mejorar terapias medicas.
EP3194439B1 (en) * 2014-09-19 2022-01-19 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
CN108431044A (zh) * 2015-10-13 2018-08-21 Siwa有限公司 抗age抗体及其使用方法
HUE058854T2 (hu) * 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával
JP2019518763A (ja) * 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
CA3059803A1 (en) * 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US20200150131A1 (en) * 2017-05-04 2020-05-14 Siwa Corporation Diagnostic advanced glycation end-product antibodies

Similar Documents

Publication Publication Date Title
JP2021534144A5 (https=)
JP2021532114A5 (https=)
JP2016519932A5 (https=)
Deshpande Enzyme immunoassays: from concept to product development
Brand et al. Secretory carrier membrane proteins 31-35 define a common protein composition among secretory carrier membranes.
BRPI0507433B8 (pt) anticorpo monoclonal recombinante ou sua parte de ligação ao antígeno, composição, ácido nucleico isolado, vetor de expressão, e, kit
JP2019522490A5 (https=)
Sheng et al. Separation of antigens and antibodies by immunoaffinity chromatography
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
NZ701444A (en) Antibodies to matrix metalloproteinase 9
NZ623541A (en) Human cgrp receptor binding proteins
Ding et al. Complement-activating IgM enhances the humoral but not the T cell immune response in mice
US20130315912A1 (en) Antibodies that Bind to Adrenomedullin and to Adrenomedullin Receptors and the Uses Thereof as Drugs
Reese et al. Purification of animal immunoglobulin G (IgG) using peptoid affinity ligands
Jones et al. Isolation of immune complexes and characterisation of their constituent antigens and antibodies in some human diseases: a review
EA201100741A1 (ru) Антитела к модифицированным пептидам ифр-1/е человека
JPS60155133A (ja) アンチ−イデイオタイプのモノクロナル抗体を採用したアンチ−イデイオタイプワクチン
US11169147B2 (en) Method for immobilizing protein on particle
WO2023196658A3 (en) Antibody compositions and optimization methods
Ma et al. The purification of natural and recombinant peptide antibodies by affinity chromatographic strategies
Reese et al. Novel peptoid-based adsorbents for purifying IgM and IgG from polyclonal and recombinant sources
Holbrook et al. OX133, a monoclonal antibody recognizing protein-bound N-ethylmaleimide for the identification of reduced disulfide bonds in proteins
CN115362171A (zh) 用于治疗冠状病毒的抗体、融合蛋白及其应用
Yu et al. Method for studying immunoglobulin G binding on hydrophobic surfaces
Nakazawa et al. Production and purification of polyclonal antibodies